Advertisement
Advertisement
U.S. markets open in 8 hours 8 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.26-0.34 (-4.41%)
At close: 04:00PM EST
7.69 +0.43 (+6.00%)
After hours: 07:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close7.59
Open7.52
Bid0.00 x 1400
Ask0.00 x 2200
Day's Range7.21 - 7.64
52 Week Range5.42 - 20.60
Volume5,581,332
Avg. Volume3,331,488
Market Cap1.145B
Beta (5Y Monthly)0.38
PE Ratio (TTM)N/A
EPS (TTM)-2.30
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.85
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IOVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Iovance Biotherapeutics, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • GlobeNewswire

    Iovance Biotherapeutics to Present at Upcoming Conferences

    SAN CARLOS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences: Piper Sandler 34th Annual Healthcare ConferenceFireside Chat: November 30, 2022 at 10:30 a.m. ET / 7:30 a.m. PTNew York, NY JMP Securities Hematology and Oncology SummitFireside Chat: December 7, 2022 at 11:00 a.m. ET / 8:00

  • Zacks

    Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug

    Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.

  • Motley Fool

    Why Iovance Biotherapeutics Is Crashing Today

    The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.

Advertisement
Advertisement